JP2018515531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515531A5 JP2018515531A5 JP2017559113A JP2017559113A JP2018515531A5 JP 2018515531 A5 JP2018515531 A5 JP 2018515531A5 JP 2017559113 A JP2017559113 A JP 2017559113A JP 2017559113 A JP2017559113 A JP 2017559113A JP 2018515531 A5 JP2018515531 A5 JP 2018515531A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 150000003839 salts Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 230000000366 juvenile effect Effects 0.000 claims 7
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 6
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 4
- 230000001185 psoriatic effect Effects 0.000 claims 4
- 208000002574 reactive arthritis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- -1 imidazopyrazinyl Chemical group 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 206010003267 Arthritis reactive Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims 2
- 208000033464 Reiter syndrome Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000036566 epidermal hyperplasia Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000012528 Juvenile dermatomyositis Diseases 0.000 claims 1
- 201000002481 Myositis Diseases 0.000 claims 1
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 1
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 201000010415 childhood type dermatomyositis Diseases 0.000 claims 1
- 208000003167 cholangitis Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 230000006866 deterioration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020054551A JP6982376B2 (ja) | 2015-05-15 | 2020-03-25 | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2448/CHE/2015 | 2015-05-15 | ||
| IN2448CH2015 | 2015-05-15 | ||
| PCT/IB2016/052773 WO2016185342A1 (en) | 2015-05-15 | 2016-05-13 | Substituted tetrahydroquinolinone compounds as ror gamma modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020054551A Division JP6982376B2 (ja) | 2015-05-15 | 2020-03-25 | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515531A JP2018515531A (ja) | 2018-06-14 |
| JP2018515531A5 true JP2018515531A5 (enExample) | 2019-06-13 |
| JP6684516B2 JP6684516B2 (ja) | 2020-04-22 |
Family
ID=57319522
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559113A Active JP6684516B2 (ja) | 2015-05-15 | 2016-05-13 | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 |
| JP2020054551A Expired - Fee Related JP6982376B2 (ja) | 2015-05-15 | 2020-03-25 | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020054551A Expired - Fee Related JP6982376B2 (ja) | 2015-05-15 | 2020-03-25 | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20180200247A1 (enExample) |
| EP (2) | EP3294713B1 (enExample) |
| JP (2) | JP6684516B2 (enExample) |
| KR (1) | KR102702236B1 (enExample) |
| CN (2) | CN108026045B (enExample) |
| AU (2) | AU2016262969C1 (enExample) |
| BR (1) | BR112017024517A2 (enExample) |
| CA (1) | CA2985547C (enExample) |
| CU (1) | CU24487B1 (enExample) |
| CY (1) | CY1124129T1 (enExample) |
| DK (1) | DK3294713T5 (enExample) |
| EA (1) | EA036679B1 (enExample) |
| ES (1) | ES2868175T3 (enExample) |
| HR (1) | HRP20210745T1 (enExample) |
| HU (1) | HUE054009T2 (enExample) |
| IL (2) | IL255522B (enExample) |
| LT (1) | LT3294713T (enExample) |
| MX (2) | MX394388B (enExample) |
| MY (1) | MY189194A (enExample) |
| PH (1) | PH12017502052A1 (enExample) |
| PL (1) | PL3294713T4 (enExample) |
| PT (1) | PT3294713T (enExample) |
| RS (1) | RS62016B1 (enExample) |
| SI (1) | SI3294713T1 (enExample) |
| SM (1) | SMT202100286T1 (enExample) |
| WO (1) | WO2016185342A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108026045B (zh) | 2015-05-15 | 2021-04-27 | 奥瑞基尼探索技术有限公司 | 用作RORγ调节剂的经过取代的四氢喹啉酮化合物 |
| JP6448867B2 (ja) | 2015-12-15 | 2019-01-09 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | イソインドール化合物 |
| TWI705958B (zh) | 2016-12-05 | 2020-10-01 | 荷蘭商領導醫藥控股責任有限公司 | ＲＯＲγ調節子 |
| CN108218845B (zh) * | 2016-12-21 | 2022-11-29 | 江苏柯菲平医药股份有限公司 | 一类色满-6-磺酰胺RORγ调节剂及其用途 |
| CA3051239C (en) | 2017-01-23 | 2023-12-19 | Magic Leap, Inc. | Eyepiece for virtual, augmented, or mixed reality systems |
| CN107129488A (zh) * | 2017-04-21 | 2017-09-05 | 湖南博奥德生物医药技术开发有限公司 | 一种艾乐替尼的制备方法 |
| WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
| CN109111418B (zh) * | 2017-06-23 | 2022-10-11 | 江苏柯菲平医药股份有限公司 | 一类2，3-二氢-1H-茚-4-磺酰胺RORγ调节剂及其用途 |
| EP3581565A1 (en) * | 2018-06-14 | 2019-12-18 | Beijing Zhibo Bio-Medical Technology Co., Ltd. | Phenyl benzyl ether derivative and preparation method and application thereof |
| CN109232416B (zh) * | 2018-10-24 | 2021-09-24 | 福州大学 | 一种合成4-三氟甲基-2-吡喃酮/吡啶酮化合物的方法 |
| AR117169A1 (es) | 2018-11-28 | 2021-07-14 | Bayer Ag | (tio)amidas de piridazina como compuestos fungicidas |
| BR112021010152A2 (pt) | 2018-12-20 | 2021-11-09 | Bayer Ag | Heterociclil piridazina como compostos fungicidas |
| EP3927329A4 (en) * | 2019-02-20 | 2022-11-23 | The Regents of the University of California | TREATMENT OF RETINIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR-Y(RORY)-DEPENDENT CANCER |
| CN109970631A (zh) * | 2019-03-26 | 2019-07-05 | 上海吉奉生物科技有限公司 | 一种5-碘-2-吡啶乙酸的合成方法 |
| CN113121463A (zh) * | 2019-12-31 | 2021-07-16 | 广东东阳光药业有限公司 | 具有双环结构的酰胺类化合物及其在药物中的应用 |
| US20230165252A1 (en) | 2020-05-27 | 2023-06-01 | Bayer Aktiengesellschaft | Active compound combinations |
| MX2022015970A (es) | 2020-06-18 | 2023-01-24 | Bayer Ag | Combinaciones de compuestos activos. |
| CN112724089B (zh) * | 2021-01-05 | 2022-08-26 | 烟台皓元生物医药科技有限公司 | 一种2-氨基-3-溴-6-氯吡嗪的合成工艺 |
| WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
| WO2024229569A1 (en) * | 2023-05-09 | 2024-11-14 | 11949098 Canada Inc. | Inverse agonists of rar related orphan receptors (rors) |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1341774T3 (da) | 2000-12-06 | 2006-06-12 | Hoffmann La Roche | Kondenserede heteroaromatiske glucokinase-aktivatorer |
| TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
| US7820704B2 (en) * | 2004-04-20 | 2010-10-26 | Transtech Pharma, Inc. | Substituted heteroaryl derivatives, compositions, and methods of use |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012027965A1 (en) * | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| WO2013029338A1 (en) * | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| US9708268B2 (en) * | 2012-04-30 | 2017-07-18 | Innov17 Llc | ROR modulators and their uses |
| MX363350B (es) * | 2012-05-08 | 2019-03-20 | Merck Sharp & Dohme | COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES. |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2014125426A1 (en) * | 2013-02-15 | 2014-08-21 | Aurigene Discovery Technologies Limited | Trisubstituted heterocyclic derivatives as ror gamma modulators |
| WO2014179564A1 (en) | 2013-05-01 | 2014-11-06 | Vitae Pharmaceuticals, Inc. | Thiazalopyrrolidine inhibitors of ror-gamma |
| WO2015017335A1 (en) * | 2013-07-30 | 2015-02-05 | Boehringer Ingelheim International Gmbh | Azaindole compounds as modulators of rorc |
| EP3041821B1 (en) * | 2013-09-05 | 2018-05-30 | Boehringer Ingelheim International GmbH | Bicylic compounds as modulators of rorgamma |
| RS58650B1 (sr) | 2013-12-05 | 2019-05-31 | Lead Pharma Holding Bv | Ror gama (rory) modulatori |
| WO2015083130A1 (en) | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
| WO2015101928A1 (en) | 2013-12-31 | 2015-07-09 | Aurigene Discovery Technologies Limited | Fused thiophene and thiazole derivatives as ror gamma modulators |
| KR102408261B1 (ko) | 2014-02-03 | 2022-06-10 | 비타이 파마슈티컬즈, 엘엘씨 | Ror-감마의 디하이드로피롤로피리딘 저해제 |
| US11084784B2 (en) | 2014-03-27 | 2021-08-10 | Piramal Enterprises Limited | ROR-gamma modulators and uses thereof |
| UA120094C2 (uk) | 2014-04-14 | 2019-10-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Сполуки як модулятори ror-гамма |
| SG11201607518RA (en) | 2014-04-16 | 2016-10-28 | Glenmark Pharmaceuticals Sa | Aryl and heteroaryl ether compounds as ror gamma modulators |
| JP2016034607A (ja) | 2014-08-01 | 2016-03-17 | 住友電気工業株式会社 | 水処理システム |
| DK3207043T6 (da) | 2014-10-14 | 2020-01-20 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridin-inhibitorer af ror-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| CN108026045B (zh) | 2015-05-15 | 2021-04-27 | 奥瑞基尼探索技术有限公司 | 用作RORγ调节剂的经过取代的四氢喹啉酮化合物 |
| WO2016193894A1 (en) | 2015-05-29 | 2016-12-08 | Glenmark Pharmaceuticals S.A. | Treatment of respiratory disorders using ror- gamma inhibitors |
| WO2017010399A1 (ja) | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物 |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| EP3868750A1 (en) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
| TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
-
2016
- 2016-05-13 CN CN201680036585.XA patent/CN108026045B/zh active Active
- 2016-05-13 US US15/574,243 patent/US20180200247A1/en not_active Abandoned
- 2016-05-13 CA CA2985547A patent/CA2985547C/en active Active
- 2016-05-13 LT LTEP16795974.1T patent/LT3294713T/lt unknown
- 2016-05-13 HR HRP20210745TT patent/HRP20210745T1/hr unknown
- 2016-05-13 CN CN202110411496.1A patent/CN113121497A/zh active Pending
- 2016-05-13 PT PT167959741T patent/PT3294713T/pt unknown
- 2016-05-13 BR BR112017024517A patent/BR112017024517A2/pt not_active Application Discontinuation
- 2016-05-13 EP EP16795974.1A patent/EP3294713B1/en active Active
- 2016-05-13 WO PCT/IB2016/052773 patent/WO2016185342A1/en not_active Ceased
- 2016-05-13 DK DK16795974.1T patent/DK3294713T5/da active
- 2016-05-13 JP JP2017559113A patent/JP6684516B2/ja active Active
- 2016-05-13 EP EP21155609.7A patent/EP3845526A1/en active Pending
- 2016-05-13 SM SM20210286T patent/SMT202100286T1/it unknown
- 2016-05-13 KR KR1020177036129A patent/KR102702236B1/ko active Active
- 2016-05-13 PL PL16795974T patent/PL3294713T4/pl unknown
- 2016-05-13 ES ES16795974T patent/ES2868175T3/es active Active
- 2016-05-13 RS RS20210598A patent/RS62016B1/sr unknown
- 2016-05-13 HU HUE16795974A patent/HUE054009T2/hu unknown
- 2016-05-13 AU AU2016262969A patent/AU2016262969C1/en active Active
- 2016-05-13 MY MYPI2017001660A patent/MY189194A/en unknown
- 2016-05-13 SI SI201631195T patent/SI3294713T1/sl unknown
- 2016-05-13 MX MX2021009561A patent/MX394388B/es unknown
- 2016-05-13 CU CU2017000144A patent/CU24487B1/es unknown
- 2016-05-13 MX MX2017014621A patent/MX385357B/es unknown
- 2016-05-13 EA EA201792515A patent/EA036679B1/ru active IP Right Revival
-
2017
- 2017-11-08 IL IL255522A patent/IL255522B/en unknown
- 2017-11-10 PH PH12017502052A patent/PH12017502052A1/en unknown
-
2019
- 2019-12-10 US US16/709,692 patent/US11229636B2/en active Active
-
2020
- 2020-03-25 JP JP2020054551A patent/JP6982376B2/ja not_active Expired - Fee Related
-
2021
- 2021-01-19 AU AU2021200330A patent/AU2021200330B2/en not_active Ceased
- 2021-05-14 CY CY20211100415T patent/CY1124129T1/el unknown
-
2022
- 2022-01-07 US US17/570,693 patent/US12377088B2/en active Active
- 2022-01-26 IL IL290153A patent/IL290153A/en unknown
-
2025
- 2025-07-09 US US19/263,745 patent/US20250332155A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515531A5 (enExample) | ||
| HRP20210745T1 (hr) | Supstituirani spojevi tetrahidrokinolinona kao ror gama modulatori | |
| JP2018536705A5 (enExample) | ||
| JP2017511357A5 (enExample) | ||
| JP2019519599A5 (enExample) | ||
| JP2014528451A5 (enExample) | ||
| SI3087075T1 (en) | SYK INHIBITORS | |
| JP2013533883A5 (enExample) | ||
| JP2013530236A5 (enExample) | ||
| JP2015527401A5 (enExample) | ||
| JP2014505033A5 (enExample) | ||
| JP2018520161A5 (enExample) | ||
| JP2018538281A5 (enExample) | ||
| HRP20190853T1 (hr) | Cot modulatori i postupci za njihovu upotrebu | |
| JP2017509689A5 (enExample) | ||
| JP2015529235A5 (enExample) | ||
| JP2018534326A5 (enExample) | ||
| JP2014505032A5 (enExample) | ||
| JP2017512186A5 (enExample) | ||
| JP2015502387A5 (enExample) | ||
| WO2007117399A2 (en) | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor | |
| JP2016508505A5 (enExample) | ||
| JP2017516826A5 (enExample) | ||
| JP2023085290A (ja) | ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| RU2010114016A (ru) | Применение пептида в качестве терапевтического средства |